• Digital Media
  • TSN News
  • Trial Watch
  • Site Watch
  • Investor Watch
  • Pharma Watch
  • Price Watch
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Nov 30, 2020 | Globe News Wire

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held virtually December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020; meetings may be requested through Piper Sandler.

A pre-recorded fireside chat with Ms. Henwood is now available on the Piper Sandler conference site and on the “Events” page within the Investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential COX-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
[email protected]
[email protected]

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
[email protected]

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
[email protected]

  • Facebook
  • Twitter
  • LinkedIn

0 Comments

Popular Posts

Dr. Solomon Talks PXT3003 Taking On Charcot Marie-Tooth Disease | Podcast

Dr. Solomon Talks PXT3003 Taking On Charcot Marie-Tooth Disease | Podcast

Dr Lenze of Washington University St. Louis Talks Antidepressant Fluvoxamine Covid-19 Clinical Trial | Podcast

Dr Lenze of Washington University St. Louis Talks Antidepressant Fluvoxamine Covid-19 Clinical Trial | Podcast

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases | Podcast

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases | Podcast

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Subscribe: Newsletter
Subscribe: YouTube
Subscribe: Podcast

Advertise with us today!

24/7 News Feed

ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas

Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners

Adamas Announces Agreement to Settle Patent Litigation with Osmotica

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

See More

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Popular Links

Contact Us
Digital Media
Blog
Privacy Policy
Terms Of Use
Advertise With Us

Connect With Us

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
Copyright © TrialSite News. All Rights Reserved.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok